Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Operating Expenses (2019 - 2025)

Allogene Therapeutics' Operating Expenses history spans 7 years, with the latest figure at $44.9 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 37.44% year-over-year to $44.9 million; the TTM value through Sep 2025 reached $227.4 million, down 23.66%, while the annual FY2024 figure was $273.2 million, 16.66% down from the prior year.
  • Operating Expenses for Q3 2025 was $44.9 million at Allogene Therapeutics, down from $56.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $99.1 million in Q1 2023 and bottomed at $44.9 million in Q3 2025.
  • The 5-year median for Operating Expenses is $71.8 million (2024), against an average of $73.6 million.
  • The largest annual shift saw Operating Expenses surged 30.4% in 2022 before it plummeted 37.44% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $73.9 million in 2021, then surged by 30.4% to $96.4 million in 2022, then fell by 11.71% to $85.1 million in 2023, then decreased by 28.94% to $60.5 million in 2024, then decreased by 25.77% to $44.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Operating Expenses are $44.9 million (Q3 2025), $56.8 million (Q2 2025), and $65.2 million (Q1 2025).